A novel drug reduces the monthly frequency of seizure in adults with focal epilepsy

The effect of a novel Kv7.2/Kv7.3 potassium channel opener XEN1101 in reducing monthly seizure frequency in adults.

Genomic conservation in Thailand’s mangroves

In this interview, Wirulda Pootakham, the Director of Thailand’s National Omic Centre, talks to NewsMedical about genomic conservation in Thailand’s mangroves.

December 6, 2024

Federal judge dismisses longstanding suit over Bristol Myers’ $74B Celgene buyout

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 1, 2024

Catalyst licenses Santhera Pharmaceuticals’ vamorolone

Vamorolone has received orphan drug status in the US to treat Duchenne muscular dystrophy. Credit: StudioMolekuul / shutterstock.com. Santhera Pharmaceuticals and Catalyst Pharmaceuticals have signed

June 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.